Non-small cell lung cancer

Score 7.1 = 2.1 leading Phase 2+ trials + 1 other trial roles + 4 talks + 0 posters. 2 of 3 trials are Phase 2+.

• ASCO 2026 8506 (proffered paper) · Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
• ESMO 2026 LBA66 (late breaking) · Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study

• Ph1NCT07912268 · Jiangsu Simcere Pharmaceutical Co., Ltd. · Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Ph3NCT05668988 · Dizal Pharmaceuticals · A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
• Ph2NCT06498986 · Sichuan Baili Pharmaceutical Co., Ltd. · A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Score 6 = 6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT05642195 · National Cancer Institute (NCI) · Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
• Ph1/Ph2NCT06694454 · National Cancer Institute (NCI) · Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Score 5.9 = 5.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07741344 · Chinese University of Hong Kong · Study of Robotic Assisted/Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC
• Ph2NCT07722182 · Chinese University of Hong Kong · Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC

Score 5.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 4 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 LBA67 (late breaking) · Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study
• ESMO 2026 LBA71 (late breaking) · PANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKI

• Ph1/Ph2NCT06114511 · Sichuan Baili Pharmaceutical Co., Ltd. · A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Score 4.8 = 4.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07133425 · M.D. Anderson Cancer Center · A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
• Ph1/Ph2NCT07579221 · M.D. Anderson Cancer Center · Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Score 3.7 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0.5 posters. 2 of 2 trials are Phase 2+.

• ESMO 2026 2583P (poster) · Real world (RW) uptake and characteristics of patients (Pts) receiving telisotuzumab vedotin-tllv (Teliso-V) in non-small cell lung cancer (NSCLC) from a US Claims Database

• Ph2NCT04940325 · Gustave Roussy, Cancer Campus, Grand Paris · Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
• Ph2NCT07360743 · UNICANCER · Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Score 3.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 LBA68 (late breaking) · Phase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) in previously treated nonsquamous non-small cell lung cancer (NSCLC)

• Ph3NCT06284317 · ETOP IBCSG Partners Foundation · A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Score 3.1 = 2.9 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07293247 · Alliance for Clinical Trials in Oncology · A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
• Ph2NCT04062708 · Alliance Foundation Trials, LLC. · CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07902921 · National Cancer Institute (NCI) · STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07889232 · VA Office of Research and Development · Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07597070 · University of Florida · Universal Immunization to Fortify Immunotherapy Efficacy and Response

Score 3 = 2.9 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph2NCT07293247 · Alliance for Clinical Trials in Oncology · A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
• Ph1NCT03824327 · Ohio State University Comprehensive Cancer Center · Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Score 3 = 1 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 LBA62 (late breaking) · ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE

• Ph2NCT05714891 · Canadian Cancer Trials Group · Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07761910 · Indiana University · Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06449313 · Georgetown University · Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07718672 · Roswell Park Cancer Institute · Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07388524 · National Cancer Institute (NCI) · Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07835789 · NRG Oncology · Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07576725 · Fred Hutchinson Cancer Center · Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07135882 · Trans Tasman Radiation Oncology Group · Primary Radiotherapy In MEtastatic Lung Cancer

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07597070 · University of Florida · Universal Immunization to Fortify Immunotherapy Efficacy and Response

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07709585 · Guangzhou University of Traditional Chinese Medicine · Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07878871 · Hunan Province Tumor Hospital · Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07846358 · Genfleet Therapeutics (Shanghai) Inc. · This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07322341 · University of Washington · SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07874490 · NYU Langone Health · Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07890636 · Ruijin Hospital · Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07874464 · Sun Yat-sen University · Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07890636 · Ruijin Hospital · Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07149649 · Swiss Cancer Institute · Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07393555 · SWOG Cancer Research Network · Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07890636 · Ruijin Hospital · Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC

Score 2.8 = 2.2 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph3NCT06732401 · National Cancer Institute (NCI) · Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
• Ph1NCT06616623 · Dwight Owen · Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
• Ph1/Ph2NCT03831932 · National Cancer Institute (NCI) · Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07158489 · Swiss Cancer Institute · Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07549061 · Shanghai Chest Hospital · Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07636785 · VM Discovery, Inc. · A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

Score 2.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• AACR 2026 CT231 (proffered paper) · Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC

• Ph3NCT05221840 · AstraZeneca · A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Score 2.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ESMO 2026 LBA5 (presidential) · Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC

• Ph2NCT05118854 · M.D. Anderson Cancer Center · A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05830058 · City of Hope Medical Center · Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
• Ph2NCT06014827 · City of Hope Medical Center · Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT03999710 · Memorial Sloan Kettering Cancer Center · Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
• Ph2NCT07323732 · Memorial Sloan Kettering Cancer Center · A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease